Lai, Daniel

The clonal and mutational evolution spectrum of primary triple-negative breast cancers

Shah, S. P., Roth, A., Goya, R., Oloumi, A., Ha, G., Zhao, Y., Turashvili, G., Ding, J., Tse, K., Haffari, G., et al. (2012) · Nature

Cancer Genomics and DiagnosticsBreast Cancer Treatment Studies

Cited by 1,967

Molecular and genetic characterization of MHC deficiency identifies EZH2 as therapeutic target for enhancing immune recognition

Ennishi, D., Takata, K., Béguelin, W., Duns, G., Mottok, A., Farinha, P., Bashashati, A., Saberi, S., Boyle, M., Meissner, B., et al. (2019) · Cancer Discovery

Lymphoma Diagnosis and TreatmentCancer Immunotherapy and Biomarkers

Cited by 318

Results of the phase I CCTG IND.231 trial of CX-5461 in patients with advanced solid tumors enriched for DNA-repair deficiencies

Hilton, J., Gelmon, K., Bedard, P. L., Tu, D., Xu, H., Tinker, A. V., Goodwin, R., Laurie, S. A., Jonker, D., Hansen, A. R., et al. (2022) · Nature Communications

DNA and Nucleic Acid ChemistryPARP inhibition in cancer therapy

Cited by 155

Luminal breast epithelial cells of BRCA1 or BRCA2 mutation carriers and noncarriers harbor common breast cancer copy number alterations

Williams, M. J., Oliphant, M. U. J., Au, V., Liu, C., Baril, C., O’Flanagan, C., Lai, D., Beatty, S., Van Vliet, M., Yiu, J. C., et al. (2024) · Nature Genetics

Cancer Genomics and DiagnosticsBRCA gene mutations in cancer

Cited by 34